ストックスクリーナーアプリを入手
14.52
1.72%
0.28
Urogen Pharma Ltd (URGN) 最新ニュース
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or - GlobeNewswire
UroGen Pharma stock holds Buy rating at H.C. Wainwright on Phase 3 trial progress By Investing.com - Investing.com South Africa
Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking - simplywall.st
What UroGen Pharma Ltd.'s (NASDAQ:URGN) 84% Share Price Gain Is Not Telling You - 富途牛牛
URGN: Analyst Reiterates Buy Rating with $25 Price Target | URGN Stock News - GuruFocus
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA - GuruFocus
UroGen completes enrollment in phase 3 bladder cancer trial - Investing.com
UroGen Pharma Completes Patient Enrollment in Phase 3 UTOPIA Trial for UGN-103 in Bladder Cancer Treatment - Quiver Quantitative
UroGen completes enrollment in phase 3 bladder cancer trial By Investing.com - Investing.com South Africa
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - The Manila Times
Breakthrough Bladder Cancer Drug Advances: 99 Patients Enrolled in Phase 3 Trial of Next-Gen Treatment - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen ... - Bluefield Daily Telegraph
UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer - MSN
11 Best Hot Stocks to Buy According to Wall Street Analysts - Insider Monkey
UroGen Pharma awards special bonuses to executives following FDA approval - Investing.com
UroGen Pharma Approves Bonuses After FDA Approval - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming DeadlinesURGN - PR Newswire
URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff ... - Bluefield Daily Telegraph
URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. - GlobeNewswire
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Eastern Progress
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - 富途牛牛
Urogen Pharma (NASDAQ:URGN) Short Interest Down 29.9% in May - Defense World
HC Wainwright Decreases Earnings Estimates for Urogen Pharma - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.URGN - FinancialContent
UroGen Pharma Ltd (NASDAQ: URGN) Stock: A Value Hunter’s Investment? - Stocksregister
H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy - MSN
UroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst Upgrade - Defense World
FDA approves UroGen’s Zusduri to treat recurrent bladder cancer - PharmaTimes
UroGen Pharma (NASDAQ:URGN) Upgraded to “Buy” at HC Wainwright - Defense World
UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT - GlobeNewswire
UroGen Investor Drops Cancer Drug Suit Following FDA Approval - Bloomberg Law News
Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about ... - Eagle-Tribune
Investors who lost money on UroGen Pharma Ltd.(URGN) should - GlobeNewswire
URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for - GlobeNewswire
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky Before July 28, 2025 to Join Class Action - ACCESS Newswire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
HC Wainwright Upgrades UroGen Pharma to Buy From Neutral, $50 Price Target - MarketScreener
UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025URGN - PR Newswire
Lost Money on UroGen Pharma Ltd. (URGN)? Urged to Join Class Action Before July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
URGN SHAREHOLDER NOTICE: BFA Law Alerts UroGen Pharma Ltd. Investors to Contact the Firm before Expiration of July 28 Class Action Deadline - Newsfile
Scotiabank Raises UroGen Pharma (NASDAQ:URGN) Price Target to $47.00 - Defense World
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - PR Newswire
UroGen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
UroGen continues to climb after bladder cancer drug approval - MSN
URGN SHAREHOLDERS: UroGen Pharma Ltd. Investors are - GlobeNewswire
UroGen Pharma (NASDAQ:URGN) Shares Gap Up After Analyst Upgrade - Defense World
UroGen Pharma Ltd. (URGN) Faces Securities Class Action - GlobeNewswire
URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Victoria Advocate
Goldman Sachs Increases Price Target for UroGen Pharma (URGN) Af - GuruFocus
UroGen Pharma Gains Amid Analyst Ratings in Biopharma Sector Russell 1000 - Kalkine Media
UroGen Pharma price target raised to $31 from $10 at Oppenheimer - Investing.com India
UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote - insights.citeline.com
UroGen Pharma (URGN) Receives Price Target Boost to $31 After Zusduri Approval | URGN Stock News - GuruFocus
Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week - Benzinga
UroGen Pharma (URGN) Sees Price Target Doubled by Scotiabank | URGN Stock News - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha
Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Opt - GuruFocus
0.14%
1.26%
大文字化:
|
ボリューム (24 時間):